27 related articles for article (PubMed ID: 27125890)
1. Facilitating Clinical Research through the Health Information Exchange: Lipid Control as an Example.
Zhu VJ; Tu W; Rosenman MB; Overhage JM
AMIA Annu Symp Proc; 2010 Nov; 2010():947-51. PubMed ID: 21347118
[TBL] [Abstract][Full Text] [Related]
2. Response to 'comment on "associations of statin use with glycemic traits and incident type 2 diabetes"'.
Ahmadizar F; Stricker BH
Br J Clin Pharmacol; 2020 Dec; 86(12):2540-2541. PubMed ID: 32441344
[No Abstract] [Full Text] [Related]
3. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
[TBL] [Abstract][Full Text] [Related]
4. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
6. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
[TBL] [Abstract][Full Text] [Related]
7. Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin use history among postmenopausal women.
Ma Y; Persuitte GM; Andrews C; Hovey KM; LaMonte MJ; Culver AL; Manson JE; Phillips LS; Liu S; Eaton C; Martin LW; Howard BV; Balasubramanian R; Bird CE; Ockene IS; Sturgeon SR; Ockene JK; Tinker L; Nassir R; Rossouw J
Eur J Epidemiol; 2016 Aug; 31(8):747-61. PubMed ID: 27188186
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies).
Teramoto T; Kobayashi M; Uno K; Takagi Y; Matsuoka O; Sugimoto M; Inoue S; Minami F; Baccara-Dinet MT
Am J Cardiol; 2016 Jul; 118(1):56-63. PubMed ID: 27184170
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
Rimbert A; Pichelin M; Lecointe S; Marrec M; Le Scouarnec S; Barrak E; Croyal M; Krempf M; Le Marec H; Redon R; Schott JJ; Magré J; Cariou B
Atherosclerosis; 2016 Jul; 250():52-6. PubMed ID: 27179706
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
Henry CA; Lyon RA; Ling H
Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Statin Indication and Dose Intensification Among Type 2 Diabetic Patients at a Tertiary Hospital.
Fisseha PY; Baye AM; Beyene MG; Makonnen E
Diabetes Metab Syndr Obes; 2024; 17():1157-1169. PubMed ID: 38469106
[TBL] [Abstract][Full Text] [Related]
12. Factors Affecting Adherence to Lipid-lowering Drugs: A Scoping Review.
Said AH; Abd Rahim IS; Mohamad Zaini NNB; Saiful Nizam NIB
Oman Med J; 2023 Jul; 38(4):e523. PubMed ID: 37736054
[TBL] [Abstract][Full Text] [Related]
13. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
14. Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study.
de Vries FM; Voorham J; Hak E; Denig P
Int J Clin Pract; 2016 Jun; 70(6):482-92. PubMed ID: 27125890
[TBL] [Abstract][Full Text] [Related]
15. Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients.
de Vries FM; Voorham J; Hak E; Denig P
Curr Med Res Opin; 2015 Dec; 31(12):2197-206. PubMed ID: 26359331
[TBL] [Abstract][Full Text] [Related]
16. Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design.
de Vries FM; Denig P; Vegter S; Bos HJ; Postma MJ; Hak E
Curr Med Res Opin; 2015 Apr; 31(4):595-602. PubMed ID: 25629791
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
18. LDL cholesterol response and statin adherence among high-risk patients initiating treatment.
Vupputuri S; Joski PJ; Kilpatrick R; Woolley JM; Robinson BE; Farkouh ME; Yun H; Safford MM; Muntner P
Am J Manag Care; 2016 Mar; 22(3):e106-15. PubMed ID: 26978237
[TBL] [Abstract][Full Text] [Related]
19. Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors.
Hsu CY; Chen WJ; Chen HM; Tsai HY; Hsiao FY
J Clin Pharm Ther; 2021 Apr; 46(2):415-423. PubMed ID: 33180353
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
